Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves new pain medication
What is Non-Opioid Pain Medication? Journavx Approved by FDA
The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.
FDA approves new, non-opioid painkiller Journavx
The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.
FDA approves Vertex’s non-opioid painkiller, first new kind of pain medicine in decades
CNBC's Becky Quick reports on the latest news.
WFMJ
4h
FDA approves non-opioid pain medication
The Food and Drug Administration on Tuesday approved Journavx, the first drug in a new class of non-opioid pain medications, ...
BioSpace
1h
Axsome’s Migraine Medicine Clears FDA Bar
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Black boxes recovered
Los Angeles wildfire updates
Activists call for boycott
Apologizes for old tweets
Ebola outbreak in Uganda
Nashville bids for franchise
'As Tears Go By' singer dies
Asteroid may hit Earth
Searching for joyriders
Top leaders asked to resign
To raise hourly pay
S3 release date revealed
Inmate's transfer blocked
Deputy shooting sentence
Confirmed interior secretary
Weekly jobless claims fall
Shiffrin finishes 10th
Sexual misconduct accusation
Ground stop amid IT outage
Ex-worker admits to theft
Cause of death revealed
Recuses self from Act 10 suit
FDA approves painkiller
Michigan priest loses license
Hamas confirms death
Olympic gold medalist dies
Blames DEI for crash
2 more victims in indictment
DOJ sues to block deal
Feedback